Business Context and Reporting Period
Company: IMMUCELL CORP
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended September 30, 2003
Business Overview: The Company operates in a single segment focused on the development, acquisition, manufacture, and sale of products to improve the health and productivity of cows for the dairy and beef industry. Key products include First Defense and Wipe Out Dairy Wipes. The Company is currently prioritizing the development of "Mast Out," a new product utilizing Nisin as an alternative to antibiotics for treating mastitis.
Key Financial Metrics
| Metric | 9 Months Ended Sep 30, 2003 | 9 Months Ended Sep 30, 2002 | 3 Months Ended Sep 30, 2003 | 3 Months Ended Sep 30, 2002 |
|---|---|---|---|---|
| Total Revenues | $2,532,550 | $4,839,410 | $788,573 | $1,385,595 |
| Net Income (Loss) | $539,241 | $176,911 | $(37,751) | $30,479 |
| Net Income Per Share (Diluted) | $0.19 | $0.06 | $(0.01) | $0.01 |
| Cash & Cash Equivalents | $2,773,178 | $1,323,336 (End of period 2002) | $2,773,178 | $2,355,970 (End of period 2002) |
| Short-term Investments | $1,582,047 | $787,046 | $1,582,047 | $787,046 |
| Net Cash from Operating Activities | $1,337,556 | $331,689 | N/A | N/A |
| Long-term Debt | $0 | $0 | $0 | $0 |
| Working Capital | $5,336,485 | $4,227,642 | $5,336,485 | $4,227,642 |
Note: Gross margin on product sales was 56% for the nine months ended Sep 30, 2003, compared to 47% in the prior year period.
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased 48% for the nine-month period and 43% for the quarter compared to 2002. This is primarily due to the early termination of a product license (Kamar Heatmount Detector) effective October 1, 2002, which eliminated approximately $2.2 million in sales for the nine-month 2002 period.
- Profitability Surge: Despite lower revenues, Net Income for the nine months increased significantly from $176,911 to $539,241. This was driven by a one-time gain of $1,100,000 recorded in Q1 2003 from the sale of the Company's 50% interest in the AgriCell Company, LLC joint venture.
- Quarterly Loss: The Company reported a net loss of $37,751 for the quarter ended September 30, 2003, compared to a net income of $30,479 in the same period in 2002. This loss was influenced by increased R&D expenses for the "Mast Out" product development.
- Expense Reduction: Sales and marketing expenses decreased by 64% for the nine-month period, largely due to the cessation of marketing activities for the terminated license product.
- Liquidity Improvement: Cash and short-term investments increased by approximately $1.2 million year-over-year, bolstered by strong operating cash flows and the joint venture sale proceeds.
Guidance, Outlook, and Risks
- Product Development: The primary focus is the development of "Mast Out." Pre-pivotal efficacy and safety studies were initiated in July 2003. The Company anticipates initiating pivotal FDA trials in Q1 2004, with completion expected in 2004.
- Manufacturing Investment: The Company is investing approximately $400,000 in facility modifications to produce Nisin in-house, aiming to reduce costs and improve quality control. As of September 30, 2003, $44,000 had been invested, with the remainder expected in Q4 2003.
- Market Conditions: Sales of existing products have been negatively affected by declining milk prices paid to producers, though some industry reports indicate improvement.
- Risks:
- Regulatory approval risks for new products (Mast Out).
- Market acceptance and pricing risks.
- Impact of the National Do Not Call Registry on telemarketing efforts (though less impactful for products sold via veterinarian distributors).
- Reliance on a single business segment and a small number of customers (one customer accounted for 19% of sales in the nine-month period).
- Capital Resources: Management believes current capital resources are sufficient to meet working capital requirements and finance operations for at least the next twelve months.
Investor Verification Checklist
- One-Time Gains: Verify the sustainability of the $1.1 million gain from the AgriCell joint venture sale, which significantly inflated 2003 net income.
- R&D Burn Rate: Monitor the $247,000 in outside laboratory expenses for "Mast Out" development and the timeline for FDA pivotal trials.
- Revenue Concentration: Assess the risk associated with 94% of product sales coming from the U.S. dairy and beef industry and the reliance on a single customer for 19% of sales.
- Deferred Revenue: Review the $400,000 in deferred revenue from the Maine Technology Institute grant, noting the contingent payback obligation upon commercialization.
- Stock Repurchase Plan: Note that the Company repurchased only 5,900 shares under its 100,000 share plan due to share prices trading above the target level.